Kornimate/medical-research-clean huggingface dataset:
hematopoietic stem cell transplant for fanconi anemia

Conditions: Fanconi Anemia

Summary: the trial proposed is a single arm phase ii treatment protocol designed to examine engraftment, toxicity, graft-versus-host disease, and ultimate disease-free survival following a novel cytoreductive regimen including busulfan, cyclophosphamide and fludarabine and anti-thymocyte globulin (atg- a non-chemotherapy drug whose role is to kill your immune system) for the treatment of patients with fanconi anemia who have severe aplastic anemia (saa), or myelodysplastic syndrome (mds) or acute myelogenous leukemia (aml), lacking hla-genotypically identical donors using stem cell transplants derived from (1) hla-compatible unrelated donors or (2) hla haplotype-mismatched related donors.

we are currently recruiting patients.

Eligibility criteria:
inclusion criteria: * fanconi anemia (confirmed by mitomycin c or deb chromosomal breakage testing and one of the following hematological diagnoses: severe aplastic anemia, myelodysplastic syndrome, acute myelogenous leukemia * karnofsky or lansy performance scale \> or = to 70%. * must have adequate cardiac, hepatic, renal and pulmonary function. * must have 7/8 or 8/8 available unrelated donor. exclusion criteria: * pregnant or breastfeeding. * active cns leukemic involvement * active uncontrolled viral, bacterial or fungal infection * positive for hiv.

Keywords: fanconi anemia hematopoietic stem cell transplant
impact of covid-19 vaccination on serum 25-hydroxyvitamin d level

Conditions: Acne Vulgaris; Vitamin D Deficiency; COVID-19

Summary: vitamin d plays a pivotal but still not well understood role in the immune response to coronavirus disease (covid-19) infection and vaccination. many studies also showed a high negative correlation between the severity of inflammatory disease and serum 25-hydroxyvitamin d levels. patients with acne vulgaris often had deteriorated skin condition after covid-19 vaccination. therefore, this study aimed to investigate the relationship of covid-19 vaccination with serum 25-hydroxyvitamin d level and severity of acne vulgaris.

vitamin d is known to be related with calcium and bone metabolism. recently, vitamin d has been shown to play an important role in innate and acquired immunity, cytokine release, inflammatory response, and may be associated with a reduced risk of infection. studies have reported that serum 25-hydroxyvitamin d concentrations are significantly lower in covid-19 infected patients than in uninfected patients. in addition, it has been shown that people with higher serum 25-hydroxyvitamin d level would produce significantly more antibodies after covid-19 vaccination.thus, it is clear that vitamin d plays a pivotal but still not well understood role in the immune response to covid-19 infection and vaccination. patients with inflammatory skin diseases (e.g., psoriasis, atopic dermatitis, acne vulgaris, hair loss, idiopathic urticaria, etc.) are often observed to have deteriorated skin condition after covid-19 vaccination, which not only affects the patient's quality of life, but also seriously affects the patient's willingness to complete vaccination. since many studies have shown a high negative correlation between the severity of inflammatory disease and serum 25-hydroxyvitamin d levels, it is likely that the covid-19 vaccination also impacts serum 25-hydroxyvitamin d levels. therefore, this study aimed to analyze the changes in serum 25-hydroxyvitamin d levels and acne severity in patients with acne vulgaris before and after the third dose of covid-19 vaccine.

Eligibility criteria:
inclusion criteria: 1. age of ≥ 20 years and \< 65 years 2. diagnosis of acne vulgaris 3. the one will receive the third dose of covid-19 vaccine 4. signing informed consent exclusion criteria: 1. history of covid-19 infection 2. currently taking vitamin-d, steroid, or any drugs for acne vulgaris. 3. coagulopathy 4. having any chronic inflammation disease, immunity-related disease, diabetes, mellitus, kidney disease, or liver disease. 5. have acute inflammation disease, for example, upper respiratory infection or urinary tract infection 6. pregnancy or lactation 7. history of cancer or any major systematic disease
colposcopy findings among women with high risk hpv other than hpv 16/18 and normal cytology

Conditions: Human Papillomavirus Infection

Summary: abnormal cervical cytology was the most common reason for women being referred to the colposcopy unit. we prospectively included the women with negative cytology (negative for intraepithelial lesions or malignancy (nilm)) and positive high riskhpv test other than hpv 16 or hpv 18. comparing the immediate colposcopy findings among women with high risk hpv other than hvpv16/18 and negative cytology and determine positive predictive values for cin2+ of other high risk hpv genotypes


Eligibility criteria:
inclusion criteria: * negative cytology (negative for intraepithelial lesions or malignancy (nilm)) and positive hrhpv test other than hpv 16 or hpv 18 exclusion criteria: * previous diagnosis for cervical cancer previous diagnosis for vaginal cancer previous diagnosis for cervical dysplasia previous diagnosis for ascus previous history of cervical conisation or hysterectomy previous history ofhysterectomy

Keywords: human papilloma virus negative for intraepithelial lesions or malignancy hpv16 hpv18
axillary phonophoresis versus post isometric facilitation in the treatment of shoulder adhesive capsulitis

Conditions: Adhesive Capsulitis of Shoulder

Summary: the aim of this study is to compare the effect of axillary phonophoresis versus post isometric facilitation in subjects with adhesive capsulitis

adhesive capsulitis is a common cause of shoulder pain and disability and also a condition involving glen humeral pain and loss of motion. it is characterized by significant restriction of both active and passive motion that occurs in the absence of a known intrinsic shoulder disorder. the intervention strategies for ac include a trial of conservative therapy followed by more invasive procedures.it may be primary-onset is generally idiopathic or secondary- results from known cause. clinically, patients may present with pain and mild restriction of movement which can lead to a gross loss of function predisposing factor or surgical event . it is most frequent in women, diabetic population and patient older than 40 years .it is described as having 3 stages. stage ⅰ involves pain (freezing or painful stage) and lasts from 3 to 9 months and is characterized by an acute synovitis of the glen humeral joint. stage ⅱ (frozen or transitional stage) includes pain and restricted movement and lasts from 4 to 12 months. stage ⅲ (thawing stage) involves painless restriction and lasts from 12 to 42 months. contributing factors include diabetes mellitus, stroke, thyroid disorder, dupuytren disease, complex regional pain syndrome and metabolic syndrome. axillary phonophoresis and post isometric facilitation play a major role in the treatment of adhesive capsulitis so this trial was conducted to determine which one has superiority. this trial has three groups. two experimental and one control group. pain ,function, pressure pain threshold will be measured.

Eligibility criteria:
inclusion criteria: * the patient age will range from 30to 40years old from both sexes (male and female). * all recruited subjects in the 2nd stage of adhesive capsulitis (transitional stage). * the patient will be diagnosed and referred by orthopedist as adhesive capsulitis. * the diagnosis will be confirmed by shoulder mri. * the diagnosis will be confirmed by shrug test. * the patient will be referred by anterior shoulder pain or anterolateral shoulder pain. * inclusion requirement include two or more of the following pain complaints: grooming ones hair, scratching your back and getting dressed, overhead activities or difficulty in the action of throwing the ball and giving a high -five. * all patients will sign the informed consent before joining the study. exclusion criteria: * previous fracture with or without internal fixation in the shoulder joint * any previous surgery in the shoulder joint and patient with tendon calcification * local corticosteroid injection to the affected shoulder within the last three months or recent ones (michener et al, 2004). * neuromuscular disease * rotator cuff tear * history of metastatic cancer or diagnosis of cancer within 12 months * unstable angina

Keywords: adhesive capsulitis post isometric facilitation axillary phonophoresis
cd19-targeted car t cell autotransfusion for the treatment of recurrent/refractory b-cell acute lymphoblastic leukemia/lymphoblastic lymphoma in children with cd19+

Conditions: B Lymphocytic Leukemia; B Lymphoblastic Lymphoma

Summary: to evaluate the safety and efficacy of bic-19gg, bic-2019, bic-2219 in the treatment of relapsed/refractory b acute lymphoblastic leukemia/lymphoblastic lymphoma in children


Eligibility criteria:
inclusion criteria: 1, age 3-18 years old (including boundary value), male and female; 2. the patient was clinically diagnosed as relapsed/refractory b acute lymphoblastic leukemia/lymphoblastic lymphoblastic patients with tumors who meet one of the following conditions: • complete marrow response (mrd\>1%) or not achieved after at least 2 courses of standardized induction regimen chemotherapy complete response at the molecular level and immunology (characterized by specific molecular markers and immunophenotypes prior to treatment) patients, did not turn negative after treatment); * recurrence during chemotherapy, early recurrence after drug withdrawal (\<12 months) or late recurrence after complete remission (≥ 12 months) and did not achieve complete remission after 1 course of standard induction regimen (mrd\>1%); * recurrence after bone marrow transplantation; * simple bone marrow, simple extramedullary (testicular leukemia, central nervous system leukemia) or combined recrudescence 3. lansky score ≥60; 4, the treatment related antigen test result is positive (cd19/cd20/cd22); 5. the expected survival period from the signing date of the informed consent is more than 3 months; 6, hgb≥70g/l (blood transfusion); 7, liver and kidney function, cardiopulmonary function meet the following requirements: 1. creatinine ≤1.5×uln; 2. left ventricular ejection fraction ≥50%; 3. blood oxygen saturation \>90%; 4. total bilirubin ≤1.5×uln; alt and ast≤2.5 x uln.- exclusion criteria: * 1, severe cardiac insufficiency, left ventricular ejection fraction \<50%; 2, have a history of severe lung function impairment; 3. combined with other advanced malignant tumors; 4, combined with serious infection and can not be effectively controlled; 5, combined with serious autoimmune disease or congenital immune deficiency; 6, active hepatitis (hepatitis b virus deoxyribonucleic acid \[hbvdna\] or hepatitis c virus ribonucleic acid \[hcvrna\] positive); 7, human immunodeficiency virus (hiv) infection or known acquired immunodeficiency syndrome (aids), or syphilis infection; 8. have a history of severe allergy to biological products (including antibiotics); 9. patients with allogeneic hematopoietic stem cell transplantation still had acute graft-versus-host response (gvhd) one month after immunosuppressant discontinuation; 10, the presence of other serious physical or mental illnesses or abnormalities in laboratory tests that may increase the risk of participating in the study or interfere with the study results, as well as patients deemed unsuitable for participation in the study by the investigator.
efficacy and safety of meloxicam (mobicox®) in mexican population with rheumatic diseases

Conditions: Osteoarthritis

Summary: study to evaluate the efficacy and safety of meloxicam (mobicox®) in mexican population with rheumatic diseases.


Eligibility criteria:
inclusion criteria: * none exclusion criteria: * hypersensitivity to meloxicam or to other nsaids * history of asthma, angioedema or urticaria secondary to nsaids * pregnancy or lactation * recent or current history of peptic ulcer disease, severe renal failure, severe hepatic failure * age below of 12 years.
novalign intramedullary fixation system (ifs) for the treatment of humeral fractures

Conditions: Fracture

Summary: this post-market clinical study is being done to evaluate the use of the novalign™ intramedullary fixation system in the treatment of humeral fractures.

this is an observational, prospective, nonrandomized open label, post-market clinical study, designed to evaluate the use a flexible intramedullary fixation device used in the treatment of fractures of the humerus. this is a multicentre trial.

Eligibility criteria:
inclusion criteria: * humeral fracture * surgical intervention can be performed within 14 days of injury (injury being day 0 for this particular criteria) * fully functioning contralateral limb (e.g., hand, arm, shoulder) * age 18 years or older and skeletally mature exclusion criteria: * intraarticular fractures or those involving shoulder or elbow of the index arm * pathologic fracture (e.g., tumor involvement, osteomalacia, etc.; osteoporosis is not an exclusion) * evidence of neurologic injury in the index arm, including compartment syndrome or radial nerve palsy * additional upper body injuries (e.g., upper extremity, abdominal, thoracic, neck or head injury) that may affect or inhibit the evaluation of the index or contralateral arm, shoulder, elbow, etc or would not allow the patient to follow or comply with appropriate post-operative regimens * any previous bodily injury or surgery that may interfere with function or evaluation of index or contralateral arm, shoulder, elbow, etc.

Keywords: fracture humerus intramedullary fixation
a multicentre trial to determine the efficacy and safety of ad-337 in the treatment of fibromyalgia

Conditions: Fibromyalgia

Summary: this is a multicentre, randomized, double-blind, placebo controlled, parallel group exploratory study to investigate the efficacy, safety and tolerability of ad 337 in the treatment of fibromyalgia in female subjects.


Eligibility criteria:
inclusion criteria: * female * age 18-65 * meet acr 1990 criteria for classification of fibromyalgia * able and willing to discontinue cns active therapies exclusion criteria: * if pain is not primarily due to fibromyalgia * current or prior history of serious psychiatric disorder * pregnant/breastfeeding * qtc \> 470ms * failure to respond to 2 or more adequate regimes of different classes of antidepressants.

Keywords: acr 1990 fibromyalgia fibromyalgia impact questionnaire
inhalational anesthesia vs tiva in endoscopic tympanoplasty

Conditions: Perforated Eardrum

Summary: this study aims to prospectively compare surgical field quality and intraoperative blood loss between general inhalational anesthesia to total intravenous anesthesia (tiva) alone in subjects undergoing endoscopic ear surgery. a secondary objective is to compare rates of emergence delirium and total recovery time between the two groups.

in sinus surgery, tiva has been described as a possible advantage in the use of endoscopic ear surgery. however, to date, there are no studies that examine blood loss, surgical field quality, and recovery in tiva compared to inhalational anesthesia in the setting of endoscopic ear surgery. the hypothesis is that in patients who undergo endoscopic tympanoplasty, those who receive tiva will have reduced intraoperative blood loss, improved surgical field quality, and reduced emergence agitation than those who receive inhalational anesthesia. this study will be a prospective double-blinded randomized control trial consisting of subjects undergoing endoscopic tympanoplasty surgery to assess intraoperative blood loss, surgical field quality, rates of emergence delirium, and recovery time.

Eligibility criteria:
inclusion criteria: * individuals of all ages * scheduled to undergo an endoscopic tympanoplasty exclusion criteria: * individuals with anticoagulation disorders * those receiving anticoagulation therapy currently

Keywords: tympanoplasty inhalational anesthesia total intravenous anesthesia intraoperative blood loss
heat waves and the elderly - cooling modalities

Conditions: Aging; Hyperthermia

Summary: the purpose of this study is to assess how well cooling modalities work in reducing cardiovascular stress of the elderly to heat wave conditions

heat waves are lethal and cause a disproportionate number of deaths in the elderly relative to any other age group. such deaths are primarily cardiovascular, not hyperthermia itself, in origin. the central hypothesis of this work is that cardiovascular stress during heat wave conditions in the elderly can be reduced by applying low-energy cooling modalities. comprehensive cardiovascular and thermal responses in the elderly will be evaluated during exposure to two prolonged heat wave conditions: hot and humid (replicating the 1995 chicago heat wave), very hot and dry (replicating the 2018 los angeles heat wave). with each of these heat wave conditions individuals will be exposed to the following cooling modalities: no cooling (control), water spray, fan use, and fan use plus water spray.

Eligibility criteria:
inclusion criteria: * 65 years of age or older * free of any significant underlying medical problems based upon a detailed medical history and physical exam exclusion criteria: * known heart disease * other chronic medical conditions requiring regular medical therapy including cancer, diabetes, uncontrolled hypertension, and uncontrolled hypercholesterolemia etc; * abnormality detected on routine screening suggestive of provokable ischemia or previously undetected cardiac disease or resting left bundle branch block on screening electrocardiogram. * current smokers, as well as individuals who regularly smoked within the past 3 years * subject with a body mass index ≥31 kg/m2 * pregnant individuals

Keywords: aging heat wave cardiovascular low-energy cooling
a study to compare three doses of t-20 when given in combination with abacavir, amprenavir, ritonavir, and efavirenz to hiv-infected adults

Conditions: HIV Infections

Summary: the purpose of this study is to see if it is safe and effective to give t-20, a new type of anti-hiv drug, with a combination of other anti-hiv drugs. the other anti-hiv drugs used are abacavir (abc), amprenavir (apv), ritonavir (rtv), and efavirenz (efv). three different doses of t-20 are tested.

patients are assigned to one of four groups. three dose groups receive a background antiretroviral regimen (abc, apv, rtv, and efv) and t-20, which is given at one of three doses on a twice-daily regimen. the fourth group (control) receives the background antiretroviral regimen alone. for each treatment group, 17 patients are enrolled. treatment is administered for 16 weeks, followed by a 32-week treatment extension, and a 2-week follow-up period. the following are assessed throughout the trial: safety parameters (as measured by hematology, clinical chemistry, urinalysis, and treatment-emergent adverse events); virologic and immunologic activity; phenotypic and genotypic resistance; t-20 plasma levels; and pharmacokinetics of t-20 and oral antiretrovirals. the total study duration is 1 year.

Eligibility criteria:
inclusion criteria patients may be eligible for this study if they: * are hiv-positive. * have an hiv level (viral load) between 400 and 100,000 copies/ml at the screening visit. * have taken at least 1 pi (protease inhibitor) for at least 16 weeks, and have had no interruptions in their most recent pi-containing anti-hiv drug regimen. * are at least 18 years old. * agree to abstinence or use of 2 effective methods of birth control, including a barrier method, during the study. exclusion criteria patients will not be eligible for this study if they: * have ever taken an nnrti (nonnucleoside reverse transcriptase inhibitor). * have an opportunistic (hiv-related) infection. * have had an unexplained fever of at least 38.5 c for 7 days in a row within 30 days prior to screening. * have had diarrhea lasting at least 15 days within 30 days prior to screening. * have ever taken abacavir, amprenavir, or efavirenz (abc, apv, or efv). * have certain genetic characteristics (drug resistance mutations) that could change the way a drug acts in the body. * are allergic to any of the study medications. * have a tumor other than certain skin or cervical cancers. * are on chemotherapy that cannot be discontinued during the study. * are taking an investigational drug within 30 days prior to screening. * have ever received an hiv vaccine. * are taking certain medications. * abuse drugs or alcohol. * have hemophilia or another blood clotting disorder. * have had an organ transplant. * are pregnant or breast-feeding.

Keywords: hiv-1 dose-response relationship, drug drug therapy, combination vx 478 anti-hiv agents pentafuside abacavir efavirenz
a study to evaluate the efficacy and safety of shr0302 in patients with ankylosing spondylitis

Conditions: Ankylosing Spondylitis

Summary: this study is to evaluate the efficacy and safety of different doses of jak1 inhibitor shr0302 in subjects with active ankylosing spondylitis.


Eligibility criteria:
inclusion criteria: * provide signed informed consent. * as diagnosis consistent with the modified new york criteria for as (1984); * participant must have baseline disease activity as defined by having a bath ankylosing spondylitis disease activity index (basdai) score \>= 4 and a patient's assessment of total back pain score \>= 4 based on a 0 - 10 numeric rating scale (nrs) at the screening and baseline visits. * participant has had an inadequate response to at least two nonsteroidal anti-inflammatory drugs (nsaids) over an at least 4-week period in total at maximum recommended or tolerated doses, or participant has an intolerance to or contraindication for nsaids as defined by the investigator. * if subjects are taking permitted csdmards or low-dose corticosteroid orally at baseline , the stable doses should have lasted for more than 4 weeks already. * bmi ≥18 kg/m2 exclusion criteria: * pregnant women or refuse to receive contraception during the study. * lab abnormality within 4 weeks of randomization as follows: wbc count \<3.0×10\^9/l；neutrophil count\<1.5×10\^9/l;hemoglobin level\<90.0 g/l ; platelet count \<100×10\^9/l; ast or alt levels greater than the upper limit of normal; hbsag or hcv or hiv antibody positivity. * history of other autoimmune diseases ; history of cancer or infection including tuberculosis and hepatitis; history of important cardiovascular events or thrombotic diseases. * previous treatment with jak inhibitor or cytotoxic drugs; bdmards within 6 months of randomization; other strong immunosuppressants within 6 months of randomization.